The US Food and Drug Administration has thus far not given SIGA Technologies, Inc “any indication” that it is thinking about using the emergency use authorization pathway for the company’s Tpoxx (tecovirimant), an antiviral that may help treat monkeypox, the company’s Chief Scientific Officer Dennis Hruby told the Pink Sheet.
This could change, Hruby acknowledged in a 5 August interview, given the 4 August public health emergency declaration under Section...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?